
Breast Cancer Market
Description
Breast Cancer Market Report and Forecast 2024-2032
The breast cancer market was valued at USD 31.9 billion in 2023, driven by the increasing prevalence of breast cancer, especially among women, coupled with advancements in targeted therapies like HER2 inhibitors and immunotherapy. The market is projected to grow at a CAGR of 9.1% during the forecast period of 2024-2032, and likely to reach a market value of USD 64 billion by 2032.
Breast Cancer Market Analysis
Breast cancer is a malignant tumor originating from breast cells, primarily affecting women but also occurring in men. Its progression varies, and treatment depends on factors like tumor size, stage, and type. Treatment options include surgery, chemotherapy, hormone therapy, and targeted therapies. The breast cancer market is expanding due to advances in diagnostics, treatment options, and increasing awareness of early detection and prevention.
Market Drivers
Rising Incidence of Breast Cancer: The growing number of breast cancer cases, particularly among ageing populations, is propelling demand for advanced treatments. Increasing risk factors such as lifestyle changes and genetic predisposition are further accelerating the need for better therapeutic interventions and research.
Technological Advancements: Breakthroughs in molecular imaging and genomic testing are enabling earlier diagnosis and more precise treatment plans. These innovations are improving patient outcomes, reducing treatment times, and facilitating personalised medicine, all contributing to market growth.
Government Initiatives and Funding: Governments globally are allocating significant resources to breast cancer awareness and research. Programmes aimed at early detection, combined with financial support for clinical trials, are expediting the development of new therapies and improving healthcare infrastructure, thereby enhancing market expansion.
Expanding Access to Healthcare: Increasing healthcare accessibility, especially in developing regions, is enabling early diagnosis and better treatment of breast cancer. Improved healthcare infrastructure and awareness campaigns in these areas are enhancing patient survival rates and driving the market forward.
Emerging Therapies: New immunotherapies and targeted drug therapies, including treatments for advanced and resistant forms of breast cancer, are showing promising results. These advancements are revolutionising breast cancer treatment, offering more effective and personalised approaches, which is pushing the market growth.
Challenges
Side Effects of Therapies: Many current breast cancer treatments, including chemotherapy, radiation, and hormonal therapies, are associated with severe side effects. These adverse effects can affect the patient's quality of life, leading to poor treatment adherence and reduced long-term efficacy.
Limited Awareness in Developing Regions: Despite global efforts to increase awareness, certain low-income regions still face challenges related to insufficient screening, delayed diagnosis, and lack of access to treatment facilities, limiting the overall effectiveness of cancer care.
Drug Resistance: Resistance to chemotherapy and targeted therapies remains a significant challenge, particularly in cases of metastatic breast cancer. Drug resistance reduces treatment efficacy over time, complicating disease management and necessitating ongoing research into alternative therapies.
Logistical Challenges in Clinical Trials: Conducting large-scale clinical trials, especially in underdeveloped regions, is often hampered by logistical, financial, and ethical barriers. These challenges slow the progress of developing and approving new treatments, impacting market growth.
Future Opportunities
Personalised Medicine: Advances in genetic profiling and biomarker research are paving the way for more personalised treatment plans for breast cancer patients. These targeted approaches are improving treatment efficacy, minimising side effects, and enhancing patient outcomes.
Development of Biosimilars: Biosimilars offer a more cost-effective alternative to expensive biologic drugs used in breast cancer treatment. As patents for several biologics expire, the development and approval of biosimilars provide an opportunity to improve accessibility to treatments.
Increased Demand for Non-invasive Diagnostics: The development of non-invasive diagnostic techniques, such as liquid biopsies, is revolutionising early breast cancer detection. These methods allow for safer, quicker, and more frequent monitoring, improving patient prognosis and expanding the diagnostic market.
Growth of Telemedicine: Telemedicine is playing a critical role in breast cancer care by enabling remote consultations and follow-up care, particularly in underserved or rural regions. This trend is expanding access to care and ensuring continuous patient monitoring, driving the market.
Immunotherapy Innovations: Ongoing research into immunotherapies for hormone receptor-positive and HER2-positive breast cancers is yielding promising results. These innovations provide new options for patients who have not responded to conventional treatments, offering significant market growth potential.
Breast Cancer Market Trends
The industry is evolving rapidly, driven by technological innovations and advancements in various practices. As continuous research uncovers new insights across sectors, several key trends are emerging, shaping the future direction of the market. These trends are expected to significantly influence the landscape, improving outcomes, enhancing precision, and expanding access to advanced solutions across products, therapies, and services.
Breast Cancer Market Segmentation
Market Breakup by Treatment Type
Market Breakup by Cancer Type
Market Breakup by Route of Administration
Market Breakup by End User
Market Breakup by Region
Breast Cancer Market Competitive Landscape
Major players in the breast cancer market include AstraZeneca, Pfizer, Inc., Novartis AG, Amgen Inc., F-Hoffmann-La Roche Ltd, GSK plc, Eli Lilly and Company, Teva Pharmaceuticals Ltd., and AbbVie Inc. These companies are at the forefront of developing innovative therapies, conducting extensive research and clinical trials, and expanding their global presence.
Key Questions Answered in the Report
What are the key growth drivers for the breast cancer market?
How is the rise in hormonal therapies affecting the breast cancer treatment landscape?
What are the latest advancements in immunotherapy for breast cancer?
Which regions are experiencing the highest growth in breast cancer treatment?
How are government initiatives contributing to breast cancer awareness?
What challenges do patients face in accessing affordable breast cancer treatment?
How is precision medicine transforming breast cancer therapy?
What role do biosimilars play in reducing the cost of breast cancer treatment?
How is telemedicine shaping follow-up care for breast cancer patients?
What are the latest trends in breast cancer clinical trials?
How is the demand for personalised medicine influencing the breast cancer market?
What are the key barriers to breast cancer treatment in developing countries?
Key Benefits for Stakeholders
The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the breast cancer market from 2017-2032.
The research report provides the latest information on the market drivers, challenges, and opportunities in the breast cancer market.
The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders analyze the level of competition within the breast cancer industry and its attractiveness.
The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.
*Please Note:* The report will take 7 business days to complete, after order confirmation.
The breast cancer market was valued at USD 31.9 billion in 2023, driven by the increasing prevalence of breast cancer, especially among women, coupled with advancements in targeted therapies like HER2 inhibitors and immunotherapy. The market is projected to grow at a CAGR of 9.1% during the forecast period of 2024-2032, and likely to reach a market value of USD 64 billion by 2032.
Breast Cancer Market Analysis
Breast cancer is a malignant tumor originating from breast cells, primarily affecting women but also occurring in men. Its progression varies, and treatment depends on factors like tumor size, stage, and type. Treatment options include surgery, chemotherapy, hormone therapy, and targeted therapies. The breast cancer market is expanding due to advances in diagnostics, treatment options, and increasing awareness of early detection and prevention.
Market Drivers
Rising Incidence of Breast Cancer: The growing number of breast cancer cases, particularly among ageing populations, is propelling demand for advanced treatments. Increasing risk factors such as lifestyle changes and genetic predisposition are further accelerating the need for better therapeutic interventions and research.
Technological Advancements: Breakthroughs in molecular imaging and genomic testing are enabling earlier diagnosis and more precise treatment plans. These innovations are improving patient outcomes, reducing treatment times, and facilitating personalised medicine, all contributing to market growth.
Government Initiatives and Funding: Governments globally are allocating significant resources to breast cancer awareness and research. Programmes aimed at early detection, combined with financial support for clinical trials, are expediting the development of new therapies and improving healthcare infrastructure, thereby enhancing market expansion.
Expanding Access to Healthcare: Increasing healthcare accessibility, especially in developing regions, is enabling early diagnosis and better treatment of breast cancer. Improved healthcare infrastructure and awareness campaigns in these areas are enhancing patient survival rates and driving the market forward.
Emerging Therapies: New immunotherapies and targeted drug therapies, including treatments for advanced and resistant forms of breast cancer, are showing promising results. These advancements are revolutionising breast cancer treatment, offering more effective and personalised approaches, which is pushing the market growth.
Challenges
Side Effects of Therapies: Many current breast cancer treatments, including chemotherapy, radiation, and hormonal therapies, are associated with severe side effects. These adverse effects can affect the patient's quality of life, leading to poor treatment adherence and reduced long-term efficacy.
Limited Awareness in Developing Regions: Despite global efforts to increase awareness, certain low-income regions still face challenges related to insufficient screening, delayed diagnosis, and lack of access to treatment facilities, limiting the overall effectiveness of cancer care.
Drug Resistance: Resistance to chemotherapy and targeted therapies remains a significant challenge, particularly in cases of metastatic breast cancer. Drug resistance reduces treatment efficacy over time, complicating disease management and necessitating ongoing research into alternative therapies.
Logistical Challenges in Clinical Trials: Conducting large-scale clinical trials, especially in underdeveloped regions, is often hampered by logistical, financial, and ethical barriers. These challenges slow the progress of developing and approving new treatments, impacting market growth.
Future Opportunities
Personalised Medicine: Advances in genetic profiling and biomarker research are paving the way for more personalised treatment plans for breast cancer patients. These targeted approaches are improving treatment efficacy, minimising side effects, and enhancing patient outcomes.
Development of Biosimilars: Biosimilars offer a more cost-effective alternative to expensive biologic drugs used in breast cancer treatment. As patents for several biologics expire, the development and approval of biosimilars provide an opportunity to improve accessibility to treatments.
Increased Demand for Non-invasive Diagnostics: The development of non-invasive diagnostic techniques, such as liquid biopsies, is revolutionising early breast cancer detection. These methods allow for safer, quicker, and more frequent monitoring, improving patient prognosis and expanding the diagnostic market.
Growth of Telemedicine: Telemedicine is playing a critical role in breast cancer care by enabling remote consultations and follow-up care, particularly in underserved or rural regions. This trend is expanding access to care and ensuring continuous patient monitoring, driving the market.
Immunotherapy Innovations: Ongoing research into immunotherapies for hormone receptor-positive and HER2-positive breast cancers is yielding promising results. These innovations provide new options for patients who have not responded to conventional treatments, offering significant market growth potential.
Breast Cancer Market Trends
The industry is evolving rapidly, driven by technological innovations and advancements in various practices. As continuous research uncovers new insights across sectors, several key trends are emerging, shaping the future direction of the market. These trends are expected to significantly influence the landscape, improving outcomes, enhancing precision, and expanding access to advanced solutions across products, therapies, and services.
- Shift Towards Targeted Drug Therapies
- Rising Popularity of Hormone Therapy
- Emphasis on Early Detection
- Growth of Outpatient Treatment Options
- Increased Focus on Biomarkers
- Expansion of Clinical Trials
Breast Cancer Market Segmentation
Market Breakup by Treatment Type
- Chemotherapy
- Hormonal therapy
- Aromatase Inhibitors
- Selective Estrogen Receptor Modulators (SERMs)
- Others
- Surgery
- Immunotherapy
- Targeted Drug Therapy
- Ribociclib
- Palbociclib
- Abemaciclib
- Others
- Others
Market Breakup by Cancer Type
- Hormone Receptor
- HER2+
Market Breakup by Route of Administration
- Oral
- Parenteral
- Others
Market Breakup by End User
- Hospitals
- Clinics
- Cancer Centers
- Research Laboratories
- Others
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- India
Breast Cancer Market Competitive Landscape
Major players in the breast cancer market include AstraZeneca, Pfizer, Inc., Novartis AG, Amgen Inc., F-Hoffmann-La Roche Ltd, GSK plc, Eli Lilly and Company, Teva Pharmaceuticals Ltd., and AbbVie Inc. These companies are at the forefront of developing innovative therapies, conducting extensive research and clinical trials, and expanding their global presence.
Key Questions Answered in the Report
What are the key growth drivers for the breast cancer market?
How is the rise in hormonal therapies affecting the breast cancer treatment landscape?
What are the latest advancements in immunotherapy for breast cancer?
Which regions are experiencing the highest growth in breast cancer treatment?
How are government initiatives contributing to breast cancer awareness?
What challenges do patients face in accessing affordable breast cancer treatment?
How is precision medicine transforming breast cancer therapy?
What role do biosimilars play in reducing the cost of breast cancer treatment?
How is telemedicine shaping follow-up care for breast cancer patients?
What are the latest trends in breast cancer clinical trials?
How is the demand for personalised medicine influencing the breast cancer market?
What are the key barriers to breast cancer treatment in developing countries?
Key Benefits for Stakeholders
The industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the breast cancer market from 2017-2032.
The research report provides the latest information on the market drivers, challenges, and opportunities in the breast cancer market.
The study maps the leading, as well as the fastest-growing, regional markets. It further enables stakeholders to identify the key country-level markets within each region.
Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders analyze the level of competition within the breast cancer industry and its attractiveness.
The competitive landscape allows stakeholders to understand their competitive environment and provides insight into the current positions of key players in the market.
*Please Note:* The report will take 7 business days to complete, after order confirmation.
Table of Contents
250 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Breast Cancer Market Overview – 8 Major Markets
- 3.1 Breast Cancer Market Historical Value (2017-2023)
- 3.2 Breast Cancer Market Forecast Value (2024-2032)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Breast Cancer Overview
- 5.1 Guidelines and Stages
- 5.2 Pathophysiology
- 5.3 Screening and Diagnosis
- 5.4 Treatment Pathway
- 6 Patient Profile
- 6.1 Patient Profile Overview
- 6.2 Patient Psychology and Emotional Impact Factors
- 6.3 Risk Assessment and Treatment Success Rate
- 7 Breast Cancer Market - Epidemiology Scenario and Forecast – 8 Major Markets
- 7.1 8MM Epidemiology Scenario Overview (2018-2034)
- 7.1.1 Prevalence, by Country
- 7.1.1.1 United States
- 7.1.1.2 United Kingdom
- 7.1.1.3 EU4
- 7.1.1.4 India
- 7.1.1.5 Japan
- 7.1.2 Diagnosed Cases, by Country
- 7.1.2.1 United States
- 7.1.2.2 United Kingdom
- 7.1.2.3 EU4
- 7.1.2.4 India
- 7.1.2.5 Japan
- 7.1.3 Treatment Seeking Rate, by Country
- 7.1.3.1 United States
- 7.1.3.2 United Kingdom
- 7.1.3.3 EU4
- 7.1.3.4 India
- 7.1.3.5 Japan
- 8 Breast Cancer Market Landscape – 8 Major Markets
- 8.1 Breast Cancer Market: Developers Landscape
- 8.1.1 Analysis by Year of Establishment
- 8.1.2 Analysis by Company Size
- 8.1.3 Analysis by Region
- 8.2 Breast Cancer Market: Product Landscape
- 8.2.1 Analysis by Treatment Type
- 8.2.2 Analysis by Cancer Type
- 8.2.3 Analysis by Route of Administration
- 9 Breast Cancer Market Challenges and Unmet Needs
- 9.1 Treatment Pathway Challenges
- 9.2 Compliance and Drop-Out Analysis
- 9.3 Awareness and Prevention Gaps
- 10 Cost of Treatment
- 11 Breast Cancer Market Dynamics
- 11.1 Market Drivers and Constraints
- 11.2 SWOT Analysis
- 11.2.1 Strengths
- 11.2.2 Weaknesses
- 11.2.3 Opportunities
- 11.2.4 Threats
- 11.3 PESTEL Analysis
- 11.3.1 Political
- 11.3.2 Economic
- 11.3.3 Social
- 11.3.4 Technological
- 11.3.5 Legal
- 11.3.6 Environment
- 11.4 Porter’s Five Forces Model
- 11.4.1 Bargaining Power of Suppliers
- 11.4.2 Bargaining Power of Buyers
- 11.4.3 Threat of New Entrants
- 11.4.4 Threat of Substitutes
- 11.4.5 Degree of Rivalry
- 11.5 Key Demand Indicators
- 11.6 Key Price Indicators
- 11.7 Industry Events, Initiatives, and Trends
- 11.8 Value Chain Analysis
- 12 Breast Cancer Market Segmentation (2018-2034) - 8 Major Markets
- 12.1 Breast Cancer Market (2018-2034) by Treatment Type
- 12.1.1 Market Overview
- 12.1.2 Chemotherapy
- 12.1.3 Hormonal therapy
- 12.1.3.1 Aromatase Inhibitors
- 12.1.3.2 Selective Estrogen Receptor Modulators (SERMs)
- 12.1.3.3 Others
- 12.1.4 Surgery
- 12.1.5 Immunotherapy
- 12.1.6 Targeted Drug Therapy
- 12.1.6.1 Ribociclib
- 12.1.6.2 Palbociclib
- 12.1.6.3 Abemaciclib
- 12.1.6.4 Others
- 12.1.7 Others
- 12.2 Breast Cancer Market (2018-2034) by Cancer Type
- 12.2.1 Market Overview
- 12.2.2 Hormone Receptor
- 12.2.3 HER2+
- 12.3 Breast Cancer Market (2018-2034) by Route of Administration
- 12.3.1 Market Overview
- 12.3.2 Oral
- 12.3.3 Parenteral
- 12.3.4 Others
- 12.4 Breast Cancer Market (2018-2034) by End User
- 12.4.1 Market Overview
- 12.4.2 Hospitals
- 12.4.3 Clinics
- 12.4.4 Cancer Centers
- 12.4.5 Research Laboratories
- 12.4.6 Others
- 12.5 Breast Cancer Market (2018-2034) by Region
- 12.5.1 Market Overview
- 12.5.2 United States
- 12.5.3 EU-4 and the United Kingdom
- 12.5.3.1 Germany
- 12.5.3.2 France
- 12.5.3.3 Italy
- 12.5.3.4 Spain
- 12.5.3.5 United Kingdom
- 12.5.4 Japan
- 12.5.5 India
- 13 United States Breast Cancer Market (2018-2034)
- 13.1 United States Breast Cancer Market Historical Value (2017-2023)
- 13.2 United States Breast Cancer Market Forecast Value (2024-2032)
- 13.3 United States Breast Cancer Market (2018-2034) by Treatment Type
- 13.3.1 Market Overview
- 13.3.2 Chemotherapy
- 13.3.3 Hormonal therapy
- 13.3.3.1 Aromatase Inhibitors
- 13.3.3.2 Selective Estrogen Receptor Modulators (SERMs)
- 13.3.3.3 Others
- 13.3.4 Surgery
- 13.3.5 Immunotherapy
- 13.3.6 Targeted Drug Therapy
- 13.3.6.1 Ribociclib
- 13.3.6.2 Palbociclib
- 13.3.6.3 Abemaciclib
- 13.3.6.4 Others
- 13.3.7 Others
- 13.4 United States Breast Cancer Market (2018-2034) by Cancer Type
- 13.4.1 Market Overview
- 13.4.2 Hormone Receptor
- 13.4.3 HER2+
- 13.5 United States Breast Cancer Market (2018-2034) by Route of Administration
- 13.5.1 Market Overview
- 13.5.2 Oral
- 13.5.3 Parenteral
- 13.5.4 Others
- 13.6 United States Breast Cancer Market (2018-2034) by End User
- 13.6.1 Market Overview
- 13.6.2 Hospitals
- 13.6.3 Clinics
- 13.6.4 Cancer Centers
- 13.6.5 Research Laboratories
- 13.6.6 Others
- 14 EU-4 and United Kingdom Breast Cancer Market (2018-2034)
- 14.1 EU-4 and United Kingdom Breast Cancer Market Historical Value (2017-2023)
- 14.2 EU-4 and United Kingdom Breast Cancer Market Forecast Value (2024-2032)
- 14.3 EU-4 and United Kingdom Breast Cancer Market (2018-2034) by Treatment Type
- 14.3.1 Market Overview
- 14.3.2 Chemotherapy
- 14.3.3 Hormonal therapy
- 14.3.3.1 Aromatase Inhibitors
- 14.3.3.2 Selective Estrogen Receptor Modulators (SERMs)
- 14.3.3.3 Others
- 14.3.4 Surgery
- 14.3.5 Immunotherapy
- 14.3.6 Targeted Drug Therapy
- 14.3.6.1 Ribociclib
- 14.3.6.2 Palbociclib
- 14.3.6.3 Abemaciclib
- 14.3.6.4 Others
- 14.3.7 Others
- 14.4 EU-4 and United Kingdom Breast Cancer Market (2018-2034) by Cancer Type
- 14.4.1 Market Overview
- 14.4.2 Hormone Receptor
- 14.4.3 HER2+
- 14.5 EU-4 and United Kingdom Breast Cancer Market (2018-2034) by Route of Administration
- 14.5.1 Market Overview
- 14.5.2 Oral
- 14.5.3 Parenteral
- 14.5.4 Others
- 14.6 EU-4 and United Kingdom Breast Cancer Market (2018-2034) by End User
- 14.6.1 Market Overview
- 14.6.2 Hospitals
- 14.6.3 Clinics
- 14.6.4 Cancer Centers
- 14.6.5 Research Laboratories
- 14.6.6 Others
- 15 Japan Breast Cancer Market
- 15.1 Japan Breast Cancer Market Historical Value (2017-2023)
- 15.2 Japan Breast Cancer Market Forecast Value (2024-2032)
- 15.3 Japan Breast Cancer Market (2018-2034) by Treatment Type
- 15.3.1 Market Overview
- 15.3.2 Chemotherapy
- 15.3.3 Hormonal therapy
- 15.3.3.1 Aromatase Inhibitors
- 15.3.3.2 Selective Estrogen Receptor Modulators (SERMs)
- 15.3.3.3 Others
- 15.3.4 Surgery
- 15.3.5 Immunotherapy
- 15.3.6 Targeted Drug Therapy
- 15.3.6.1 Ribociclib
- 15.3.6.2 Palbociclib
- 15.3.6.3 Abemaciclib
- 15.3.6.4 Others
- 15.3.7 Others
- 15.4 Japan Breast Cancer Market (2018-2034) by Cancer Type
- 15.4.1 Market Overview
- 15.4.2 Hormone Receptor
- 15.4.3 HER2+
- 15.5 Japan Breast Cancer Market (2018-2034) by Route of Administration
- 15.5.1 Market Overview
- 15.5.2 Oral
- 15.5.3 Parenteral
- 15.5.4 Others
- 15.6 Japan Breast Cancer Market (2018-2034) by End User
- 15.6.1 Market Overview
- 15.6.2 Hospitals
- 15.6.3 Clinics
- 15.6.4 Cancer Centers
- 15.6.5 Research Laboratories
- 15.6.6 Others
- 16 India Breast Cancer Market
- 16.1 India Breast Cancer Market Historical Value (2017-2023)
- 16.2 India Breast Cancer Market Forecast Value (2024-2032)
- 16.3 India Breast Cancer Market (2018-2034) by Treatment Type
- 16.3.1 Market Overview
- 16.3.2 Chemotherapy
- 16.3.3 Hormonal therapy
- 16.3.3.1 Aromatase Inhibitors
- 16.3.3.2 Selective Estrogen Receptor Modulators (SERMs)
- 16.3.3.3 Others
- 16.3.4 Surgery
- 16.3.5 Immunotherapy
- 16.3.6 Targeted Drug Therapy
- 16.3.6.1 Ribociclib
- 16.3.6.2 Palbociclib
- 16.3.6.3 Abemaciclib
- 16.3.6.4 Others
- 16.3.7 Others
- 16.4 India Breast Cancer Market (2018-2034) by Cancer Type
- 16.4.1 Market Overview
- 16.4.2 Hormone Receptor
- 16.4.3 HER2+
- 16.5 India Breast Cancer Market (2018-2034) by Route of Administration
- 16.5.1 Market Overview
- 16.5.2 Oral
- 16.5.3 Parenteral
- 16.5.4 Others
- 16.6 India Breast Cancer Market (2018-2034) by End User
- 16.6.1 Market Overview
- 16.6.2 Hospitals
- 16.6.3 Clinics
- 16.6.4 Cancer Centers
- 16.6.5 Research Laboratories
- 16.6.6 Others
- 17 Regulatory Framework
- 17.1 Regulatory Overview
- 17.2 US FDA
- 17.3 EU EMA
- 17.4 Japan PMDA
- 17.5 India CDSCO
- 17.6 Others
- 18 Patent Analysis
- 18.1 Analysis by Cancer Type of Patent
- 18.2 Analysis by Publication Year
- 18.3 Analysis by Issuing Authority
- 18.4 Analysis by Patent Age
- 18.5 Analysis by CPC Analysis
- 18.6 Analysis by Patent Valuation
- 19 Clinical Trials Analysis
- 19.1 Analysis by Trial Registration Year
- 19.2 Analysis by Trial Status
- 19.3 Analysis by Trial Phase
- 19.4 Analysis by Therapeutic Area
- 19.5 Analysis by Geography
- 20 Grants Analysis
- 20.1 Analysis by Year
- 20.2 Analysis by Amount Awarded
- 20.3 Analysis by Issuing Authority
- 20.4 Analysis by Grant Application
- 20.5 Analysis by Funding Institute
- 20.6 Analysis by NIH Departments
- 20.7 Analysis by Recipient Organization
- 21 Funding and Investment Analysis
- 21.1 Analysis by Funding Instances
- 21.2 Analysis by Treatment Type of Funding
- 21.3 Analysis by Funding Amount
- 21.4 Analysis by Leading Players
- 21.5 Analysis by Leading Investors
- 21.6 Analysis by Geography
- 22 Strategic Initiatives
- 22.1 Analysis by Partnership Instances
- 22.2 Analysis by Treatment Type of Partnership
- 22.3 Analysis by Leading Players
- 22.4 Analysis by Geography
- 23 Supplier Landscape
- 23.1 Market Share Analysis, By Region (Top 5 Companies)
- 23.2 AstraZeneca
- 23.2.1 Financial Analysis
- 23.2.2 Product Portfolio
- 23.2.3 Demographic Reach and Achievements
- 23.2.4 Companies News and Developments
- 23.2.5 Certifications
- 23.3 Pfizer, Inc.
- 23.3.1 Financial Analysis
- 23.3.2 Product Portfolio
- 23.3.3 Demographic Reach and Achievements
- 23.3.4 Companies News and Developments
- 23.3.5 Certifications
- 23.4 Novartis AG
- 23.4.1 Financial Analysis
- 23.4.2 Product Portfolio
- 23.4.3 Demographic Reach and Achievements
- 23.4.4 Companies News and Developments
- 23.4.5 Certifications
- 23.5 Amgen Inc.
- 23.5.1 Financial Analysis
- 23.5.2 Product Portfolio
- 23.5.3 Demographic Reach and Achievements
- 23.5.4 Companies News and Developments
- 23.5.5 Certifications
- 23.6 F-Hoffmann-La Roche Ltd,
- 23.6.1 Financial Analysis
- 23.6.2 Product Portfolio
- 23.6.3 Demographic Reach and Achievements
- 23.6.4 Companies News and Developments
- 23.6.5 Certifications
- 23.7 GSK plc
- 23.7.1 Financial Analysis
- 23.7.2 Product Portfolio
- 23.7.3 Demographic Reach and Achievements
- 23.7.4 Companies News and Developments
- 23.7.5 Certifications
- 23.8 Eli Lily and Company
- 23.8.1 Financial Analysis
- 23.8.2 Product Portfolio
- 23.8.3 Demographic Reach and Achievements
- 23.8.4 Companies News and Developments
- 23.8.5 Certifications
- 23.9 Teva Pharmaceuticals Ltd.
- 23.9.1 Financial Analysis
- 23.9.2 Product Portfolio
- 23.9.3 Demographic Reach and Achievements
- 23.9.4 Companies News and Developments
- 23.9.5 Certifications
- 23.10 AbbVie Inc.
- 23.10.1 Financial Analysis
- 23.10.2 Product Portfolio
- 23.10.3 Demographic Reach and Achievements
- 23.10.4 Companies News and Developments
- 23.10.5 Certifications
- 24 Breast Cancer Treatment Drugs - Distribution Model (Additional Insight)
- 24.1 Overview
- 24.2 Potential Distributors
- 24.3 Key Parameters for Distribution Partner Assessment
- 25 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 26 Payment Methods (Additional Insight)
- 26.1 Government Funded
- 26.2 Private Insurance
- 26.3 Out-of-Pocket
- *Additional insights provided are customisable as per client requirements.
- * The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
- *The supplier list is not exhaustive. Moreover, we can provide analysis of companies as per custom requests.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.